Skip to content

Effect of Periodontal Therapy on Asprosin in Stable Angina

Effect of Non-Surgical Periodontal Therapy on Serum Asprosin in Patients With Stable Angina

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07591844
Enrollment
60
Registered
2026-05-18
Start date
2026-05-20
Completion date
2026-10-20
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis, Stable Angina Pectoris

Keywords

Non-surgical periodontal treatment, cardiovascular disease, stable angina, asprosin, periodontitis

Brief summary

This study aims to evaluate the effect of non-surgical periodontal therapy on serum asprosin levels in patients with stable angina and periodontitis. Asprosin is a novel metabolic biomarker reported to have potential protective roles in cardiovascular diseases and inflammatory processes. The study also investigates the relationship between periodontal parameters and serum asprosin levels before and after periodontal therapy.

Detailed description

Periodontitis is a chronic inflammatory disease characterized by the destruction of the tooth-supporting tissues and has been associated with increased systemic inflammation and cardiovascular diseases. Stable angina, a clinical manifestation of coronary artery disease, is closely linked to inflammatory and metabolic pathways. Increasing evidence suggests that periodontal inflammation may contribute to cardiovascular pathology through systemic dissemination of inflammatory mediators and oxidative stress mechanisms. Asprosin is a recently identified adipokine secreted mainly from white adipose tissue and is involved in glucose metabolism, inflammatory regulation, and cardiovascular homeostasis. Previous studies have reported altered serum asprosin levels in patients with atherosclerosis, myocardial infarction, and periodontitis. However, the effect of periodontal therapy on serum asprosin levels in patients with stable angina has not yet been clinically investigated. In this clinical study, 60 individuals will be allocated into three groups: healthy controls, periodontitis patients, and patients with stable angina and periodontitis. Non-surgical periodontal therapy will be performed in periodontitis groups, while supragingival scaling and oral hygiene instructions will be provided for controls. Clinical periodontal parameters and serum asprosin levels will be evaluated at baseline and at 3-month follow-up using ELISA analysis. The study aims to determine whether periodontal therapy may influence serum asprosin levels and to evaluate the possible relationship between periodontal inflammation and metabolic-inflammatory pathways in cardiovascular disease. To the best of our knowledge, this is the first clinical study evaluating the effect of periodontal therapy on serum asprosin levels in patients with stable angina.

Interventions

Non-surgical periodontal therapy will include full-mouth scaling and root planing performed using hand instruments and/or ultrasonic devices to remove supra- and subgingival plaque and calculus.

Supragingival calculus and plaque removal with standardized oral hygiene instruction.

Sponsors

Ondokuz Mayıs University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Stable angina and periodontitis group (SAP group): Individuals diagnosed with stable angina and periodontitis who will receive non-surgical periodontal therapy, including scaling and root planing. Periodontitis group (P group): Cardiovascularly healthy individuals diagnosed with periodontitis who will receive non-surgical periodontal therapy, including scaling and root planing. Control group (C group): Periodontally and cardiovascularly healthy individuals who will receive routine professional dental cleaning and standardized oral hygiene instruction.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Willingness to participate in the study and provide written informed consent * Age 18 years or older * No periodontal treatment within the past 6 months * No use of local or systemic antibiotics within the past 3 months

Exclusion criteria

* Unwillingness to participate in the study or to provide informed consent * Age under 18 years * Use of local or systemic antibiotics for the treatment of widespread infection within the past 3 months * Receipt of periodontal treatment within the past 6 months * Pregnancy or lactation (for female participants) * History of acute myocardial infarction within the past 6 months

Design outcomes

Primary

MeasureTime frameDescription
Change in serum asprosin levels after non-surgical periodontal therapyBaseline and 3 monthsSerum asprosin concentrations (ng/mL) will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit at baseline and 3 months following non-surgical periodontal therapy.

Countries

Turkey (Türkiye)

Contacts

CONTACTSena Altintas, DDS
senaltintas144@gmail.com+905540270097
CONTACTFeyza Otan Ozden, Prof.
feyza_otan@yahoo.com
PRINCIPAL_INVESTIGATORSena Altintas, DDS

Ondokuz Mayis University Department of Periodontology

STUDY_DIRECTORFeyza Otan Ozden, Prof.

Ondokuz Mayis University Department of Periodontology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026